Le Lézard
Classified in: Health, Science and technology
Subject: PER

David Perez to Retire as President and CEO of Terumo BCT on March 31, 2019; Antoinette Gawin Named Successor

LAKEWOOD, Colo., Aug. 15, 2018 /PRNewswire/ -- Terumo BCT announced today that David Perez will retire as president and chief executive officer (CEO) of Terumo BCT and that Antoinette Gawin, executive vice president, global commercial, will succeed him in both roles. Antoinette will become president on October 1, 2018 and will become CEO at the start of fiscal year 2019 on April 1, 2019. David also serves on the Terumo Corporation board of directors and will retire from this position at the end of his current term in June 2019.

Antoinette Gawin, Terumo BCT

David has served as an exemplary leader since he began his career with Terumo BCT, then called COBE BCT, in May 1999. He guided the company through multiple changes in ownership, including Gambro BCT and CaridianBCT and when the company joined Terumo Corporation in 2011. "David is an established leader in the global blood management and transfusion medicine industry and will leave behind an enduring legacy of leadership, impact and influence. Under his leadership, the company grew revenue almost sixfold, nearing $1 billion, and introduced multiple innovative products that have fundamentally changed and improved blood transfusion and cellular therapies. I would like to thank David for his contributions over many years and wish him every success in the future," said Shinjiro Sato, President and CEO of Terumo Corporation, Terumo BCT's parent company.

David Perez said: "It has been an honor and a privilege to lead Terumo BCT and to serve on Terumo's Board of Directors. I have a deep emotional connection to the company, to our associates and customers, and to the patients we ultimately serve. When I retire, I will have been leading the company for almost 20 years and I am truly thankful for the incredible experiences that have shaped my life and will forever be part of who I am. I have complete confidence in Antoinette and her ability to build on our success and take the company to the next level by diversifying and expanding into growth areas."

Antoinette Gawin joined Terumo BCT in 2016 and has made significant contributions to the company through her strong focus on the voice of the customer. Prior to Terumo BCT, Antoinette served in leadership roles at Baxter overseeing global market access, commercial excellence and strategy. For 22 years prior to that, Antoinette worked in leadership positions at several GE subsidiaries, including GE Healthcare Technologies, GE Industrial and Power Systems, GE Information Services and GE Corporate. Living in Switzerland, London and the U.S. during her tenure at GE, she led global organizations and served in a broad range of influential roles, including chief marketing officer, chief executive officer and general manager.

Shinjiro Sato said: "I am very pleased to announce Antoinette's appointment after a very comprehensive selection process. David and I share the belief that Antoinette is the right person to lead Terumo BCT into the future. She is an outstanding leader with highly valuable experience and a strong track record of delivering growth and driving performance in healthcare."

Antoinette Gawin said: "I joined the Terumo BCT community to help shape healthcare. The solutions and clinical expertise we bring to the frontiers of medicine truly can unlock the potential of blood and cells to advance therapies. I am honored to be selected as David's successor. I'm looking forward to working with David and other leaders over the coming months to ensure a smooth handover and continue to develop plans for 2019 and beyond."

About Terumo BCT 
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with over $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and are a component of the Nikkei 225, Japan's leading stock index.

Media Contact
Terumo BCT
Bradley Hein 


Terumo BCT


These press releases may also interest you

16 fév 2019
B&G Foods Canada, ULC is recalling Victoria White Linen Collection Marinara Sauce from the marketplace because it may contain cashew which is not declared on the label. People with an allergy to cashew should not consume the recalled product...

16 fév 2019
JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

16 fév 2019
Merck , known as MSD outside the United States and Canada, today announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with Inlyta...

16 fév 2019
Pipeline Health, a community-based hospital management company, announced today that it has begun the process to close Westlake Hospital, a 230-bed hospital in Melrose Park, and plans to file an application next week with the Illinois Health...

16 fév 2019
AVEO Oncology today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian...

16 fév 2019
Vetsource®, a technology-enabled health-care services company with a platform that empowers veterinarians to deliver better patient care, has made a significant investment in Vet2Pet, the leading mobile app client engagement platform for veterinary...

News published on 15 august 2018 at 19:03 and distributed by: